CVS Health (CVS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.58
- Estimate
- $1.85
- Surprise
- +39.4%
- Revenue (period 2026-06-30)
- $106.10B
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
CVS Health (CVS) beat the $1.85 estimate with adjusted EPS of $2.58 — a large 39.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CVS Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +39.4% surprise compares with a +20.8% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Quality below floor (3.4 < 4.0)
- Reward/Risk 1.3:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $92.60
- Price target
- $103.93
- Stop
- $88.28
- Upside to target
- +12.2%
- Reward-to-risk
- 1.3:1
The stock trades at 24.4× trailing but 10.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
CVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $118.34B
- P/E (fwd)
- 10.8
- P/E (ttm)
- 24.4
- 52-week range
- $69.51–$110.68
- Off 52-week high
- 16.3%
- RSI (14)
- 66
- Volume vs avg
- 0.03×
- Score today
- 5.7/10